Capital actions spoke
Macro was quiet, so the cleanest signal was balance-sheet intent: who’s returning cash, who’s bracing, who’s adding exposure.
Dexus (DXS) moved higher on a share buyback and management saying premium office demand remains strong. For an asset-heavy REIT, capital allocation is the argument. A buyback is management saying the stock is cheap versus their view of NAV. The leasing color mattered because it tied the financial move to operations: they’re not just polishing optics, they’re saying the top end of the portfolio can still hold up.
Santos (STO) fell after an annual profit slump tied to lower commodity prices and a plan to cut headcount by 10%. The market treated it as defensive. When the commodity line rolls over, “discipline” stops sounding like optionality and starts sounding like triage.
Separately, Berkshire Hathaway disclosed increased stakes in The New York Times and Domino’s Pizza. Not a same-day catalyst, but it’s a positioning tell: patient capital is still leaning into durable cash flows and brands that don’t require a thesis document. Whatever the market does with growth multiples, Buffett keeps buying businesses where the model doesn’t need a fantasy chapter.
Credit stayed open—selectively
Credit remains the stealth macro input. It doesn’t show up on an economic calendar, but it determines who can refinance, who can invest, and who gets forced into “strategic alternatives.”
In Australia, Bain Capital Credit and UBS provided a $382 million loan to Aidacare. The equity reaction was basically a shrug, but the message is still there: private credit is available for scaled operators in defensible verticals like healthcare equipment. What matters now sits in the footnotes—use of proceeds (growth versus refi), covenant tightness, and the all-in cost of capital. Liquidity is available; it’s just not cheap or unconditional.
In rates-land, the Philippines government scheduled its first large peso bond auction since April to fund growth-support measures. That’s a straightforward local liquidity test. Strong demand keeps domestic yields contained and leaves room for private borrowers. Weak demand pushes funding costs up and tightens conditions without anyone needing to say the word “tightening.” The auction will do the talking.
Earnings: clean beats, real bridges
Fundamentals got rewarded when they were simple and clean. Longer-dated frameworks only held up when the bridge from “story” to “numbers” looked believable.
IAMGOLD (IAG) posted non-GAAP EPS of $0.70 on $1.09B revenue, both above estimates. For a commodity-linked name, beating both lines reads as execution, not just a favorable tape.
Goosehead (GSHD) guided 10–19% organic revenue growth and flagged accelerated AI investment in 2026. The setup is familiar: productivity narrative versus near-term margin drag. The market will want a timetable and a margin floor, not just ambition.
Axcelis (ACLS) forecast flat 2026 revenue, with memory growth offset by declines elsewhere. “Flat” can mean stabilization if memory actually inflects, or it can mean ceiling if non-memory demand keeps sliding. Orders and backlog tone decide which.
Cadence (CDNS) set a 2026 revenue target of $5.9B–$6.0B on AI-driven design demand. The EDA logic is intact—more AI and chip complexity drives more tooling. The risk isn’t the narrative; it’s the cycle and whether customer spend stays sticky through capex mood swings.
Halozyme (HALO) guided 2026 revenue of $1.71B–$1.81B, leaning on pipeline expansion via new subcutaneous technologies. Out-year ranges can work, but the stock still needs nearer proof points: partner activity, launch visibility, and conversion that doesn’t rely on heroic assumptions.
Capital return and clean beats were the easiest “yes” today; everything else came down to whether the numbers could actually carry the story.